All Posts Tagged With: "SLXP"
(DRE) Duke Realty Leases to Novella
Duke Realty Corp. (DRE), a real estate investment trust (REIT), recently signed an agreement with Novella Clinical to lease a property in North Carolina, located at 1700 Perimeter Park Drive in Morrisville....
(SLXP) Salix Pharmaceuticals – Bull of the Day
Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix...
(SLXP) Salix Pharmaceuticals – Bull of the Day
Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix...
(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral
We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share.
We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first...
(OPTR) Optimer Pharma Beats on One-Time Gain
Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat...
(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid
Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote...
(OPTR) Optimer Pharmaceuticals Earns FDA Panel Nod on Dificid Drug
Optimer Pharmaceuticals Inc. (OPTR) received a major boost when an advisory panel of the US Food and Drug Administration (FDA) unanimously recommended approval of its lead pipeline candidate, Dificid (fidaxomicin),...
(SLXP) Salix Pharmaceuticals Posts Narrower Third Quarter 2010 Loss
Salix Pharmaceuticals, Ltd. (SLXP) posted a loss of 5 cents per share in the third quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the guidance provided by the company...
(OPTR) Optimer Pharmaceuticals Signs Manufacturing Deal
Recently, Optimer Pharmaceuticals (OPTR) entered into a long-term supply agreement with India based Biocon Limited. The agreement is aimed at manufacturing the active pharmaceutical ingredient of fidaxomicin,...
(SLXP) Salix Pharmaceuticals Exceeds Consensus Estimates
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 45 cents per share in the first quarter of 2010, 6 cents better than the Zacks Consensus Estimate. The company had guided towards a net loss of 50...
(SLXP) Salix Pharmaceuticals Earns FDA Approval for Xifaxan
Salix Pharmaceuticals, Ltd. (SLXP) received a huge boost recently with the US approval of Xifaxan 550 mg. The Food and Drug Administration (FDA) granted approval for the use of Xifaxan 550 mg in reducing...
(SLXP) Salix Pharmaceuticals Beats Forecasts but Outlook Disappoints
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 13 cents per share in the fourth quarter, a penny better than the Zacks Consensus Estimate and company guidance of a net loss of 14 cents. Salix reported...
(SLXP) Salix Pharmaceuticals Focuses on Label Expansion
Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents....
(SLXP) Salix Pharmaceuticals Gets Good News From FDA
Salix Pharmaceuticals, Ltd. (SLXP) received good news recently when the Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee recommended the approval of Xifaxan (500 mg) for...
(SLXP) Salix Pharmaceuticals to File for IBS Indication
Salix Pharmaceuticals, Ltd. (SLXP) recently held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) related to the company’s new drug application (NDA) for rifaximin for the treatment of...
(SLXP) Salix Pharmaceuticals Beats Expectation on Xifaxan’s Strength
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 15 cents per share in the third quarter, which was significantly better than the Zacks Consensus Estimate of a net loss of 29 cents. The company reported...
(SLXP) Salix Pharmaceuticals Scores on Rifaximin Data
Shares of Salix Pharmaceuticals (SLXP) jumped 51% yesterday after the company announced positive results from two pivotal phase III trials of rifaximin for the treatment of non-constipation irritable bowel syndrome (IBS).
Two randomized,...
(SLXP) Salix Pharmaceuticals Gets Marketing Approval
Salix Pharmaceuticals, Ltd. (SLXP) received positive news yesterday when the U.S. Food and Drug Administration (FDA) granted marketing approval for Metozolv ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. Metozolv ODT received approval...
(SLXP) Salix Pharmaceuticals’ Drug Gets Priority Status
Salix Pharmaceuticals Ltd. (SLXP) yesterday announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to its new drug application (NDA) for rifaximin 550 mg. Salix is seeking approval for the use of rifaximin for the...